Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

References

• Drijkoningen JJ, Rohde GG. 2014. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 20:45–51. doi:10.1111/1469-0691.12461.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG. 2005. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 192:377–386. doi:10.1086/431521.
   PubMed Web of Science ®Google Scholar
• Janssens JP, Krause KH. 2004. Pneumonia in the very old. Lancet Infect Dis. 4:112–124. doi:10.1016/S1473-3099(04)00931-4.
   PubMed Web of Science ®Google Scholar
• Morrill HJ, Caffrey AR, Noh E, LaPlante KL. 2014. Epidemiology of pneumococcal disease in a national cohort of older adults. Infect Dis Ther. 3:19–33. doi:10.1007/s40121-014-0025-y.
   PubMedGoogle Scholar
• Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, Purdy J, Paradiso P, File TM. 2013. Distribution of 13-valent pneumococcal conjugate vaccine streptococcus pneumoniae serotypes in us adults aged 50 years with community-acquired pneumonia. J Infect Dis. 208:1813–1820. doi:10.1093/infdis/jit506.
   PubMed Web of Science ®Google Scholar
• Pletz MW, Ewig S, Rohde G, Schuette H, Rupp J, Welte T, Suttorp N, Forstner C. 2016. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine. 34:2342–2348. doi:10.1016/j.vaccine.2016.03.052.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. 2015. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 372:1114–1125. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 325:1453–1460. doi:10.1056/NEJM199111213252101.
   PubMed Web of Science ®Google Scholar
• Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med. 103;1997:281–290.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A. 2009. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 27:1504–1510. doi:10.1016/j.vaccine.2009.01.013.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D’Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340:c10004.
   Google Scholar
• Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348(18):1747–1755. doi:10.1056/NEJMoa022678.
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 1;2013:CD000422.
   PubMed Web of Science ®Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C. Effectiveness of 23-valent pneumococcal polysaccharide vaccine (ppv23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):e0169368. doi:10.1371/journal.pone.0169368.
   PubMed Web of Science ®Google Scholar
• Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, Mäkelä PH, Broome CV, Facklam RR, Tiesjema RH, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis. 1983;148:1136–1159.
   PubMed Web of Science ®Google Scholar
• Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. 2011. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 10:1143–1167. doi:10.1586/erv.11.99.
   PubMed Web of Science ®Google Scholar
• Pavia M, Foresta M, Carbone V, Angelillo I. Influenza and pneumococcal immunization in the elderly: knowledge, attitudes, and practices among general practitioners in Italy. Public Health. 117;2003:202–207.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 19:187–195. doi:10.1097/00006454-200003000-00003.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, Kumar G, Parkinson A, Hu D, Hackell J, et al. Efficacy and safety of seven valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet. 2003;362:355–431. doi:10.1016/S0140-6736(03)14776-9.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. 2003. A trial of a 9 valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 349:1341. doi:10.1056/NEJMoa030969.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381:214–222. doi:10.1016/S0140-6736(12)61854-6.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Seppä I, Kaijalainen T, Puumalainen T, Soininen A, Traskine M, Lommel P, Schoonbroodt S, Hezareh M, et al. 2016. Effectiveness of the 10-valent pneumococcal nontypeable haemophilus influenzae protein D-conjugated vaccine (PHiD-CV) against carriage and acute otitis media-a double-blind randomized clinical trial in Finland. J Pediatric Infect Dis Soc. 5:237–248. doi:10.1093/jpids/piw010.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Toropainen M, Kaijalainen T, Siira L, Lahdenkari M, Nieminen H, Syrjänen RK, Kilpi TM, Jokinen J. 2017. Direct and indirect effectiveness of the 10-valent pneumococcal conjugate vaccine against carriage in a cluster randomized trial. Ped Infect Dis J. 36:1193–1200. doi:10.1097/INF.0000000000001705.
   PubMed Web of Science ®Google Scholar
• Domínguez Á, Ciruela P, Hernández S, García-García JJ, Soldevila N, Izquierdo C, Moraga-Llop F, Díaz A, de Sevilla MF, González-Peris S, et al. 2017. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PLoS One. 12:e0183191. doi:10.1371/journal.pone.0183191.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. 2010. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 201:32–41. doi:10.1086/648593.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Active bacterial core surveillance (ABCs) report. emerging infections program network. streptococcus pneumonia. [ accessed 2018 Mar 23]. http://www.cdc.gov/abcs/reports-findings/surv-reports.html.
   Google Scholar
• Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O’Brien KL, Moore MR. 2013. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: A pooled analysis of multiple surveillance sites. PLoS Med. 10:e1001517. doi:10.1371/journal.pmed.1001517.
   PubMed Web of Science ®Google Scholar
• Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. 2011. Serotype-specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine. 29:283–288. doi:10.1016/j.vaccine.2010.10.032.
   Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Ling LP, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO. 2013. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Ped Infect Dis J. 32:203–207. doi:10.1097/INF.0b013e318275614b.
   PubMed Web of Science ®Google Scholar
• Richter SS, Diekema DJ, Hellmann KP, Dohrn CL, Riahi F, Doern GV. 2014. Changes in pneumococcal serotypes and antimicrobial resistance after the introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 58:6484–6489. doi:10.1128/AAC.03344-14.
   PubMed Web of Science ®Google Scholar
• Desai A, Sharma D, Crispell EK, Baughman W, Thomas S, Tunali A, Sherwood L, Zmitrovich A, Jerris R, Satola SW, et al. 2015. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Ped Infect Dis J. 34:1168–1174. doi:10.1097/INF.0000000000000849.
   PubMed Web of Science ®Google Scholar
• Demczuk WHB, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, et al. 2013. Serotype distribution of invasive streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol. 59:778–788. doi:10.1139/cjm-2013-0614.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. 2015. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 15:301–309. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. 2015. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 15:535–543. doi:10.1016/S1473-3099(15)70044-7.
   PubMed Web of Science ®Google Scholar
• Angoulant F, Levy C, Grimpel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, et al. 2014. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 58:918–924. doi:10.1093/cid/ciu006.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. 2013. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 369:155–163. doi:10.1056/NEJMoa1209165.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. 2014. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2:387–394. doi:10.1016/S2213-2600(14)70032-3.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Lim WS. 2015. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 45:1632–1641. doi:10.1183/09031936.00183614.
   PubMed Web of Science ®Google Scholar
• Sobanjo-ter Meulen A, Vesilari T, Malacaman EA, Shapiro SA, Dallas MJ, Hoover PA, McFetridge R, Stek JE, Marchese RD, Hartzel J, et al. 2015. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 34:186–194. doi:10.1097/INF.0000000000000516.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, Dallas M, Hartzel J, Marchese RD, Coller BAG, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. vaccine 2018;36(45):6883-6891. doi: 10.1016/j.vaccine.2018.02.113.
   Google Scholar
• Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, Hartzel J, Marchese RD, Stek JE, Abeygunawardana C, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine. 2018;36(45):6875–6882. doi: 10.1016/j.vaccine.2018.03.012.
   PubMedGoogle Scholar
• Horácio AN, Silva-Costa C, Lopes JP, Ramirez M, Melo-Cristino J. 2016. Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol. 7:1616. doi:10.3389/fmicb.2016.01616.
   PubMed Web of Science ®Google Scholar
• Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjöström K, Morfeldt E, Naucler P, Blennow M, Örtqvist Å, et al. 2016. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 47:1208–1218. doi:10.1183/13993003.01451-2015.
   PubMed Web of Science ®Google Scholar
• Oligbu G, Collins S, Andrews N, Sheppard CL, Fry NK, Slack MPE, Borrow R, Ladhani SN. 2017. Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006–2014. Clin Infect Dis. 65:1191–1198. doi:10.1093/cid/cix474.
   PubMed Web of Science ®Google Scholar
• Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (mopa4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13(9):1004–1009. doi: 10.1128/CVI.00112-06.
   PubMed Web of Science ®Google Scholar
• Marchese RD, Puchalski D, Miller P, Antonello J, Hammond O, Green T, Rubinstein LJ, Caulfield MJSikkema D. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin g serotype-specific antipneumococcal antibodies in human serum. Clin Vaccine Immunol. 2009;16(3):387–396. doi: 10.1128/CVI.00415-08.
   PubMed Web of Science ®Google Scholar
• Liang K-YZeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya: The Indian Journal of Statistics. 2000;62:134–148. http://sankhya.isical.ac.in/search/62b1/fpaper7.pdf
   Google Scholar